Last reviewed · How we verify
TNKase
TNKase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow in acute myocardial infarction.
TNKase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow in acute myocardial infarction. Used for Acute myocardial infarction (STEMI) for restoration of coronary blood flow.
At a glance
| Generic name | TNKase |
|---|---|
| Also known as | Tenecteplase, TNK |
| Sponsor | Cedars-Sinai Medical Center |
| Drug class | Fibrinolytic agent; tissue plasminogen activator (tPA) |
| Target | Fibrin; plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
TNKase (tenecteplase) is a genetically engineered variant of natural tissue plasminogen activator with enhanced fibrin specificity and longer half-life. It binds to fibrin in thrombi and catalyzes the conversion of plasminogen to plasmin, which degrades the fibrin matrix of blood clots. This fibrinolytic action rapidly restores coronary blood flow in patients experiencing acute ST-elevation myocardial infarction (STEMI).
Approved indications
- Acute myocardial infarction (STEMI) for restoration of coronary blood flow
Common side effects
- Bleeding (major and minor)
- Intracranial hemorrhage
- Hypotension
- Arrhythmias (reperfusion)
- Nausea/vomiting
Key clinical trials
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
- Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO) (PHASE3)
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well (PHASE3)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNKase CI brief — competitive landscape report
- TNKase updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI